查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
血清學檢測市場：2023年至2028年預測
市場調查報告書
商品編碼
1410033

血清學檢測市場：2023年至2028年預測

Serological Testing Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

血清學檢測市場預計在預測期內將以 4.50% 的複合年成長率成長。

血清學測試是一種實驗室測試，可分析血液樣本以檢測抗體（例如抗體）的存在，並提供有關人的免疫反應的有價值的資訊。血清學檢測產業為醫院、診所、診斷實驗室、血庫和其他依賴此類檢測的組織提供準確診斷、監測病患健康、確保輸血安全等支持，我們回應醫療機構的需求。新醫院和血庫的建立不斷增加，是擴大血清學檢測市場規模的重要促進因素。

血庫建設的蓬勃發展正在推動血清學檢測市場的成長。

血庫進行血清學檢測，以確保捐血的血液和血液製品的安全。這些測試有助於識別血液樣本中是否存在特定抗體或抗原。血庫負責進行血清學檢測，篩檢感染疾病的血液是否患有愛滋病毒、B型肝炎、C型肝炎、梅毒和其他輸血感染疾病。

醫院體力的提升是血清檢測市場擴大的原動力。

醫院使用血清學檢測，因為它們提供有關患者免疫反應的重要資訊，並有助於準確診斷和監測各種疾病。醫院依靠血清學檢測來識別抗體、檢測傳染源、評估疫苗接種狀況並確定免疫系統功能。醫院血清學檢測需求的增加是由於感染疾病流行的日益嚴重，並且隨著醫院的不斷擴大，血清學檢測的需求也會增加。根據美國醫院協會統計，美國醫院總數從2021年的6,090家醫院增加到2023年的6129家醫院。

不斷增加的公共衛生舉措正在推動血清學檢測市場的成長。

血清學測試由於能夠識別血液樣本中抗體的存在而在公共衛生測試中受到歡迎。世界各國政府正在投資測試​​基礎設施、研發和篩檢項目，以控制疾病爆發、監測人群免疫力並確保血液安全。需求加速成長。據世界衛生組織（WHO）稱，美國2020年向世衛組織和聯合國兒童基金會提供了8400萬美元，用於加強全球監測、維護實驗室網路、採購疫苗、向各國提供技術援助以及支持當地社區，發揮了重要作用在振興中。

預計亞太地區將主導市場。

亞太地區預計將在血清學檢測市場中佔據重要佔有率，因為該地區正在經歷醫療保健行業、基礎設施開拓、醫療設施和技術進步的快速擴張。這種成長推動了對血清學檢測作為重要診斷工具的需求。此外，政府對醫療保健政策和公共衛生宣傳活動的投資進一步推動了亞太地區血清學檢測產業的成長。例如，在2023-24年聯邦預算中，衛生和家庭福利部分配的預算為8915.5億盧比，比上年度2021-22年預算8620.065億盧比增加了3.43%。

高成本限制了血清學檢測市場的成長。

血清學檢測的成本可能是其採用的主要障礙，特別是在醫療保健預算有限或報銷系統無法充分涵蓋這些檢測的地區。當使用先進技術和多重檢測時，這項挑戰尤其明顯，而這通常涉及高昂的成本。高檢測成本是一個障礙，限制了血清學檢測的獲得並阻礙了其廣泛使用，普及是在資源匱乏的環境中，預算限制在醫療保健決策中發揮關鍵作用。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表

第2章調查方法

  • 調查資料
  • 先決條件

第3章執行摘要

  • 研究亮點

第4章市場動態

  • 市場促進因素
  • 市場抑制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章血清學檢測市場：依檢測類型

  • 介紹
  • 初級血清學檢測
    • 酵素結合免疫吸附測定法 (ELISA)
    • 螢光抗體測定（IFAT）
    • 免疫測量（RIA）
  • 二次血清學檢測
    • 凝集試驗
    • 補體結合試驗（CFT）
    • 沉澱試驗
  • 血清中和試驗（SNT）
    • 毒素抗毒素測試
    • 三級結合測試

第6章血清學檢測市場：依應用分類

  • 介紹
  • 輪狀病毒感染疾病
  • 肝炎
  • HIV
  • 內毒素
  • 治療藥物監測
  • 其他感染疾病

第7章血清學檢測市場：依最終使用者分類

  • 介紹
  • 醫院和診所
  • 診斷實驗室
  • 血庫
  • 其他

第8章血清學檢測市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作

第10章 公司簡介

  • Serological Research Institute（SERI）（UK）
  • Chembio Diagnostics, Inc（US）
  • Cellex（US）
  • Randox Laboratories Ltd（UK）
  • Abbott（US）
  • Bio-Rad Laboratories Inc.（US）
  • BD（US）
  • Thermo Fisher Scientific Inc.（US）
  • Ortho Clinical Diagnostics（US）
  • Quest Diagnostics Incorporated（US）
簡介目錄
Product Code: KSI061615692

The serological testing market is estimated to grow at a CAGR of 4.50% during the forecast period.

Serological testing is a laboratory test that analyses a blood sample to detect the presence of antibodies or other substances, providing valuable information about a person's immune response. The serological testing industry caters to the needs of medical institutions such as hospitals, clinics, diagnostic laboratories, and blood banks that rely on such testing for accurate diagnoses, monitoring patient health, and ensuring the safety of blood transfusions. The growing establishment of new hospitals and blood banks play vital roles as prominent drivers in augmenting the serological testing market size.

Booming blood bank establishment bolsters the serological testing market growth.

Serological testing is done in blood banks to ensure the safety of donated blood and blood products. These tests help identify the presence of specific antibodies or antigens in the blood samples. Blood banks are responsible for conducting serological tests to screen donated blood for infectious diseases, such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible infections.

The rise in hospitals' strength drives the serological market expansion.

Serological testing is used in hospitals as it provides crucial information about a patient's immune response, aiding in accurate diagnoses and monitoring of various diseases. Hospitals rely on serological tests to identify antibodies, detect infectious agents, assess vaccination status, and determine immune system function. The increasing demand for serological testing in hospitals is driven by the growing prevalence of infectious diseases and as hospitals continue to expand, demand for serological testing rises. According to the American Hospital Association, the total number of hospitals in the United States experienced an increase in 2023, reaching 6,129, compared to the previous count of 6,090 hospitals in 2021.

An increase in public health initiatives drives the serological testing market growth.

Serological testing due to its ability to identify the presence of antibodies in blood samples is experiencing a boost in public health checkups. Governments worldwide are investing in testing infrastructure, research, and development, and screening programs to control disease outbreaks, monitor population immunity, and ensure blood safety which is accelerating the demand for serological testing. According to the World Health Organization, in 2020, the United States extended a significant contribution of $84 million to WHO and UNICEF which played a vital role in bolstering global surveillance, sustaining the laboratory network, procuring vaccines, providing technical assistance to countries, and fostering community mobilization efforts.

Asia-Pacific is estimated to dominate the market.

Asia-Pacific will hold a significant share of the serological testing market as the region is experiencing rapid expansion in its healthcare sector, infrastructure development, medical facilities, and technological advancements. This growth is fuelling the demand for serological testing as a critical diagnostic tool. Moreover, government investments in healthcare policies and public health campaigns further support the growth of the serological testing industry in Asia-Pacific. For instance, in the Union Budget 2023-24, the Ministry of Health and Family Welfare received an allocation of Rs. 89,155 crore representing a growth of 3.43% from the previous year's allocation of Rs. 86,200.65 crore in 2021-22.

High cost restrains the serological testing market growth.

The cost of serological tests can be a significant hindrance to their adoption, particularly in regions with limited healthcare budgets or where reimbursement systems do not adequately cover these tests. This challenge is particularly pronounced when advanced technologies or multiplex assays are used, as they often involve higher expenses. The high cost of testing acts as a barrier, limiting access to serological testing and preventing its widespread utilization, especially in resource-constrained settings where budgetary constraints play a crucial role in healthcare decision-making.

Key Developments

  • May 2020: Thermo Fisher Scientific Inc. revealed its plans to further expand its efforts in response to the COVID-19 pandemic through a collaboration with WuXi Diagnostics and Mayo Clinic. This collaboration aims to develop a comprehensive total antibodies test for COVID-19. The combined expertise of all three organizations, including the clinical evaluation and support provided by the Mayo Clinic, has been instrumental in the development of this new serology test. By leveraging their collective capabilities, Thermo Fisher Scientific, WuXi Diagnostics, and Mayo Clinic are working together to enhance diagnostic capabilities and contribute to the ongoing global response against COVID-19.
  • April 2020: Eurofins Technologies introduced a range of CE-IVD marked serologic products designed to detect antibodies in individuals who have been exposed to the SARS-CoV-2 virus, which causes COVID-19. These newly launched products provide reliable and validated testing solutions to assess the immune response in patients, aiding in the diagnosis, monitoring, and management of COVID-19 cases. Eurofins Technologies' expansion of its serologic product portfolio strengthens the global fight against the pandemic by enhancing the availability of accurate serological testing options for healthcare providers.
  • April 2020: Roche, a leading healthcare company, developed the Elecsys Anti-SARS-CoV-2 serology test, a cutting-edge diagnostic tool that enables the detection of antibodies against the SARS-CoV-2 virus, responsible for COVID-19. This innovative serology test plays a vital role in identifying individuals who have been exposed to the virus and assessing their immune response. By determining the presence of antibodies, healthcare professionals can gain insights into a person's potential immunity against COVID-19, aiding in treatment decisions and providing valuable information for public health strategies.
  • March 2020: BD (Becton, Dickinson, and Company), a renowned global medical technology company, unveiled the Rapid Serology Test, an innovative point-of-care test that swiftly detects antibodies in blood to confirm recent or prior exposure to COVID-19. This breakthrough test provides results within a mere 15 minutes, enabling healthcare professionals to swiftly diagnose and determine the immune response of individuals. BD's introduction of the Rapid Serology Test strengthens the fight against the pandemic by offering a rapid and efficient serological testing solution.

Segmentation

By Test Type

  • Primary Serological Tests
  • Enzyme Linked Immunosorbent Assay (ELISA)
  • Immunofluorescent Antibody Technique (IFAT)
  • Radio Immunoassay (RIA)
  • Secondary Serological Tests
  • Agglutination Tests
  • Complement Fixation Tests (CFT)
  • Precipitation Tests
  • Serum Neutralization Tests (SNT)
  • Toxin-antitoxin Tests
  • Tertiary Binding Tests

By Application

  • Rotavirus
  • Hepatitis
  • HIV
  • Endotoxins
  • Therapeutic Drug Monitoring
  • Other Infectious Diseases

By End-Users

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Blood Banks
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SEROLOGICAL TESTING MARKET, BY TEST TYPE

  • 5.1. Introduction
  • 5.2. Primary Serological Tests
    • 5.2.1. Enzyme Linked Immunosorbent Assay (ELISA)
    • 5.2.2. Immunofluorescent Antibody Technique (IFAT)
    • 5.2.3. Radio Immunoassay (RIA)
  • 5.3. Secondary Serological Tests
    • 5.3.1. Agglutination Tests
    • 5.3.2. Complement Fixation Tests (CFT)
    • 5.3.3. Precipitation Tests
  • 5.4. Serum Neutralization Tests (SNT)
    • 5.4.1. Toxin-antitoxin Tests
    • 5.4.2. Tertiary Binding Tests

6. SEROLOGICAL TESTING MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Rotavirus Infections
  • 6.3. Hepatitis
  • 6.4. HIV
  • 6.5. Endotoxins
  • 6.6. Therapeutic Drug Monitoring
  • 6.7. Other Infectious Diseases

7. SEROLOGICAL TESTING MARKET, BY END USERS

  • 7.1. Introduction
  • 7.2. Hospital and Clinics
  • 7.3. Diagnostic Laboratories
  • 7.4. Blood Banks
  • 7.5. Diagnostic Laboratories
  • 7.6. Others

8. SEROLOGICAL TESTING MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Serological Research Institute (SERI) (U.K.)
  • 10.2. Chembio Diagnostics, Inc (U.S.)
  • 10.3. Cellex (U.S.)
  • 10.4. Randox Laboratories Ltd (U.K.)
  • 10.5. Abbott (U.S.)
  • 10.6. Bio-Rad Laboratories Inc. (U.S.)
  • 10.7. BD (U.S.)
  • 10.8. Thermo Fisher Scientific Inc. (U.S.)
  • 10.9. Ortho Clinical Diagnostics (U.S.)
  • 10.10. Quest Diagnostics Incorporated (U.S.)